Update on Huntington's Disease Modifying Therapies

Current Disease-Modifying Therapies

• 💡 The video provides an update on investigational disease-modifying therapies for Huntington's disease (HD).
• 📌 Several companies are developing treatments targeting the huntingtin protein or mRNA to slow or halt disease progression.

Uniqure's AMT-130 Progress

• 🚀 Uniqure's AMT-130 is an investigational adenovirus therapy using microRNA to decrease both wild-type and mutant huntingtin.
• 🧠 This therapy requires a neurosurgical procedure for direct delivery to the basal ganglia.
• 📊 Interim 24-month data showed a -0.2 cUHDRS worsening compared to -1.0 in a control group, likely from the Enroll-HD study.

Precision Therapeutics' PTC-518 Findings

• 💊 Precision Therapeutics' PTC-518 is an oral small molecule splicing inhibitor, specific for mutant huntingtin RNA.
• 🔬 Interim 12-month results from the PIVOT-HD trial demonstrated a 60% reduction in mutant huntingtin mRNA and a 35% reduction in mutant huntingtin protein.
• 📈 While "favorable results" for cUHDRS were reported, specific numerical changes were not released, making direct comparison difficult.

Other Investigational Treatments

• ✨ Skyhawk's SKY-8515, an oral small molecule splicing modulator, achieved a 72% reduction in huntingtin mRNA in healthy volunteers during Phase 1/2 studies.
• 🧬 Wave Lifesciences' WVE-003, an allele-selective antisense oligonucleotide (ASO), showed a 44-46% reduction of mutant huntingtin protein in cerebrospinal fluid.
• ⚠️ Previous therapies like Ionis HTTRX (Tominersen) and earlier Wave Lifesciences ASOs were discontinued due to not meeting disease-lowering standards or clinical endpoints.

Key Considerations for Trials

• ⚖️ Directly comparing different therapies is challenging due to varying data points and reporting metrics, such as clinical progression versus biomarker reduction.
• ✅ The cUHDRS scale is considered an appropriate and validated clinical endpoint for Huntington's disease trials.
• 💡 Using natural history studies like Enroll-HD for control groups can be a valid approach for rare diseases where placebo-controlled trials are difficult.